95 related articles for article (PubMed ID: 10912469)
1. In vitro evaluation of c7E3-Fab (ReoPro) eluting polymer-coated coronary stents.
Baron JH; Gershlick AH; Hogrefe K; Armstrong J; Holt CM; Aggarwal RK; Azrin M; Ezekowitz M; de Bono DP
Cardiovasc Res; 2000 Jun; 46(3):585-94. PubMed ID: 10912469
[TBL] [Abstract][Full Text] [Related]
2. Eptifibatide-eluting stent as an antiproliferative and antithrombotic agent: in vitro evaluation.
Chitkara K; Hogrefe K; Vasa-Nicotera M; Swanson N; Gershlick AH
J Invasive Cardiol; 2006 Sep; 18(9):417-22. PubMed ID: 16954580
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of vascular smooth muscle cell adhesion and migration by c7E3 Fab (abciximab): a possible mechanism for influencing restenosis.
Baron JH; Moiseeva EP; de Bono DP; Abrams KR; Gershlick AH
Cardiovasc Res; 2000 Dec; 48(3):464-72. PubMed ID: 11090842
[TBL] [Abstract][Full Text] [Related]
4. c7E3 Fab inhibits low shear flow modulated platelet adhesion to endothelium and surface-absorbed fibrinogen by blocking platelet GP IIb/IIIa as well as endothelial vitronectin receptor--results from patients with acute myocardial infarction and healthy controls.
Reininger AJ; Agneskirchner J; Bode PA; Spannagl M; Wurzinger LJ
Thromb Haemost; 2000 Feb; 83(2):217-23. PubMed ID: 10739376
[TBL] [Abstract][Full Text] [Related]
5. Comparative real-time effects on platelet adhesion and aggregation under flowing conditions of in vivo aspirin, heparin, and monoclonal antibody fragment against glycoprotein IIb-IIIa.
Turner NA; Moake JL; Kamat SG; Schafer AI; Kleiman NS; Jordan R; McIntire LV
Circulation; 1995 Mar; 91(5):1354-62. PubMed ID: 7867173
[TBL] [Abstract][Full Text] [Related]
6. In vitro effects of the platelet glycoprotein IIb/IIIa receptor antagonist c7E3 Fab on the activated clotting time.
Ammar T; Scudder LE; Coller BS
Circulation; 1997 Feb; 95(3):614-7. PubMed ID: 9024148
[TBL] [Abstract][Full Text] [Related]
7. Flow cytometric observations on the in vivo use of Fab fragments of a chimaeric monoclonal antibody to platelet glycoprotein IIb-IIIa.
Christopoulos C; Mackie I; Lahiri A; Machin S
Blood Coagul Fibrinolysis; 1993 Oct; 4(5):729-37. PubMed ID: 8292722
[TBL] [Abstract][Full Text] [Related]
8. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty.
EPIC Investigators
N Engl J Med; 1994 Apr; 330(14):956-61. PubMed ID: 8121459
[TBL] [Abstract][Full Text] [Related]
9. Differential effects of c7E3 Fab on thrombus formation and rt-PA-Mediated thrombolysis under flow conditions.
Huang TC; Jordan RE; Hantgan RR; Alevriadou BR
Thromb Res; 2001 Jun; 102(5):411-25. PubMed ID: 11395127
[TBL] [Abstract][Full Text] [Related]
10. Effect of platelet glycoprotein IIb/IIIa integrin blockade on activated clotting time during percutaneous transluminal coronary angioplasty or directional atherectomy (the EPIC trial). Evaluation of c7E3 Fab in the Prevention of Ischemic Complications trial.
Moliterno DJ; Califf RM; Aguirre FV; Anderson K; Sigmon KN; Weisman HF; Topol EJ
Am J Cardiol; 1995 Mar; 75(8):559-62. PubMed ID: 7887377
[TBL] [Abstract][Full Text] [Related]
11. Effects of beta3-integrin blockade (c7E3) on the response to angioplasty and intra-arterial stenting in atherosclerotic nonhuman primates.
Deitch JS; Williams JK; Adams MR; Fly CA; Herrington DM; Jordan RE; Nakada MT; Jakubowski JA; Geary RL
Arterioscler Thromb Vasc Biol; 1998 Nov; 18(11):1730-7. PubMed ID: 9812911
[TBL] [Abstract][Full Text] [Related]
12. Labeling of the internal pool of GP IIb-IIIa in platelets by c7E3 Fab fragments (abciximab): flow and endocytic mechanisms contribute to the transport.
Nurden P; Poujol C; Durrieu-Jais C; Winckler J; Combrié R; Macchi L; Bihour C; Wagner C; Jordan R; Nurden AT
Blood; 1999 Mar; 93(5):1622-33. PubMed ID: 10029591
[TBL] [Abstract][Full Text] [Related]
13. The glycoprotein IIb/IIIa antagonist c7E3 inhibits platelet aggregation in the presence of heparin-associated antibodies.
Liem TK; Teel R; Shukla S; Silver D
J Vasc Surg; 1997 Jan; 25(1):124-30. PubMed ID: 9013915
[TBL] [Abstract][Full Text] [Related]
14. Activation of platelets in platelet-rich plasma by rotablation is speed-dependent and can be inhibited by abciximab (c7E3 Fab; ReoPro).
Williams MS; Coller BS; Väänänen HJ; Scudder LE; Sharma SK; Marmur JD
Circulation; 1998 Aug; 98(8):742-8. PubMed ID: 9727543
[TBL] [Abstract][Full Text] [Related]
15. Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin receptor-activating peptide in patients treated with bolus chimeric 7E3 Fab: implications for inhibition of the internal pool of GPIIb/IIIa receptors.
Kleiman NS; Raizner AE; Jordan R; Wang AL; Norton D; Mace KF; Joshi A; Coller BS; Weisman HF
J Am Coll Cardiol; 1995 Dec; 26(7):1665-71. PubMed ID: 7594101
[TBL] [Abstract][Full Text] [Related]
16. The long-term clinical results of a platelet glycoprotein IIb/IIIa receptor blocker (Abciximab: Reopro) coated stent in patients with coronary artery disease.
Kim W; Jeong MH; Hong YJ; Lee SH; Park WS; Kim JH; Kim IS; Choi MJ; Ahn YK; Cho JG; Park JC; Cho DL; Kim H; Kang JC
Korean J Intern Med; 2004 Dec; 19(4):220-9. PubMed ID: 15683110
[TBL] [Abstract][Full Text] [Related]
17. Effect of glycoprotein IIb-IIIa receptor antagonism on platelet membrane glycoproteins after coronary stent placement.
Gawaz M; Ruf A; Neumann FJ; Pogátsa-Murray G; Dickfeld T; Zohlnhöfer D; Schömig A
Thromb Haemost; 1998 Dec; 80(6):994-1001. PubMed ID: 9869173
[TBL] [Abstract][Full Text] [Related]
18. A modified thromboelastographic method for monitoring c7E3 Fab in heparinized patients.
Greilich PE; Alving BM; O'Neill KL; Chang AS; Reid TJ
Anesth Analg; 1997 Jan; 84(1):31-8. PubMed ID: 8988995
[TBL] [Abstract][Full Text] [Related]
19. New antiplatelet agents: platelet GPIIb/IIIa antagonists.
Coller BS; Anderson K; Weisman HF
Thromb Haemost; 1995 Jul; 74(1):302-8. PubMed ID: 8578476
[TBL] [Abstract][Full Text] [Related]
20. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. The EPIC Investigators.
Topol EJ; Califf RM; Weisman HF; Ellis SG; Tcheng JE; Worley S; Ivanhoe R; George BS; Fintel D; Weston M
Lancet; 1994 Apr; 343(8902):881-6. PubMed ID: 7908357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
